Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TET3 | O43151 | 1/20 | 0.54 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.54 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.54 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.54 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.54 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.54 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1041902 | 0.98 | AKR1C1 (0.96) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL19249602 | 0.98 | AKR1C1 (0.96) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1042420 | 0.98 | AKR1C1 (0.96) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL66387 | 0.98 | AKR1C1 (0.96) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8315894 | 0.98 | AKR1C1 (0.96) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3811046 | 0.96 | AKR1C1 (0.92) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1667343 | 0.95 | AKR1C1 (0.91) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| Water SCHEMBL3811044 | 0.94 | AKR1C1 (0.88) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8105149 | 0.93 | AKR1C1 (0.88) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL11665752 | 0.93 | AKR1C1 (0.88) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 763 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094387-A | Perovskite film based on volatile additive, and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| CN-118771956-A | Carboxylic acid decarboxylation coupling conversion method using sulfur hexafluoride as oxidizing reagent | 国网安徽省电力有限公司电力科学研究院 | 2024-10-15 | — | — | CN | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| CN-117623949-A | Preparation method of pentovirine citrate | 苏州敬业医药化工有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-114388761-A | Lithium battery negative electrode material and preparation method thereof | 曾福强 | 2022-04-22 | — | — | CN | claimed |
| EP-3104847-B1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | MTA TAMOGATOTT KUTATOCSOPORTOK IRODAJA (HU) | 2020-11-11 | — | — | EP | claimed |
| CN-108623814-B | Copper-based porous coordination polymer hydrogen storage material and preparation method thereof | 中国石油化工股份有限公司 | 2020-10-16 | — | — | CN | claimed |
| CN-108912713-A | A kind of energy conservation and environmental protection plastic and preparation method thereof | 合肥万之景门窗有限公司 | 2018-11-30 | — | — | CN | claimed |
| CN-108623814-A | A kind of copper-based Porous coordination polymer hydrogen storage material and preparation method thereof | 中国石油化工股份有限公司 | 2018-10-09 | — | — | CN | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| US-6323243-B1 | AROMATIC ETHER WITH AMINE OR AMIDE GROUPS | WARNER-LAMBERT COMPANY | 2001-11-27 | — | — | US | claimed |
| WO-2000006535-A1 | TYROSINE-DERIVED COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2000-02-10 | — | — | WO | claimed |
| US-4686302-A | Simultaneous preparation of nitriles and acrylamide or methacrylamide | BASF AKTIENGESELLSCHAFT (DE) | 1987-08-11 | — | — | US | claimed |
| EP-0081756-B1 | NEW COMPOUNDS WITH ANTIINFLAMMATORY AND ANTITUSSIVE ACTIVITY, PROCESS FOR THEIR PREPARATION AND RELATIVE PHARMACEUTICAL COMPOSITIONS | MEDEA RESEARCH S.r.l. (IT) | 1985-05-15 | — | — | EP | claimed |
| EP-0081756-A1 | New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions | MEDEA RESEARCH S.r.l. (IT) | 1983-06-22 | — | — | EP | claimed |
| EP-0024172-B1 | ANTITUMOR AND IMMUNOSUPPRESSIVE 4-CARBAMOYLIMIDAZOLIUM-5-OLATE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND PRODUCTION THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-05-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | AKR1C1 2446/4885HDAC4 802/4885KMT2A 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.